CA3033971A1 - Ppar.gamma. agonist for treatment of bone disorders - Google Patents

Ppar.gamma. agonist for treatment of bone disorders Download PDF

Info

Publication number
CA3033971A1
CA3033971A1 CA3033971A CA3033971A CA3033971A1 CA 3033971 A1 CA3033971 A1 CA 3033971A1 CA 3033971 A CA3033971 A CA 3033971A CA 3033971 A CA3033971 A CA 3033971A CA 3033971 A1 CA3033971 A1 CA 3033971A1
Authority
CA
Canada
Prior art keywords
subject
int131
therapeutically effective
effective amount
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3033971A
Other languages
English (en)
French (fr)
Inventor
Dennis Lanfear
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intekrin Therapeutics Inc
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of CA3033971A1 publication Critical patent/CA3033971A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3033971A 2016-08-18 2017-08-18 Ppar.gamma. agonist for treatment of bone disorders Pending CA3033971A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
US62/376,732 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Publications (1)

Publication Number Publication Date
CA3033971A1 true CA3033971A1 (en) 2018-02-22

Family

ID=61197122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033971A Pending CA3033971A1 (en) 2016-08-18 2017-08-18 Ppar.gamma. agonist for treatment of bone disorders

Country Status (11)

Country Link
US (1) US20190167660A1 (enExample)
EP (1) EP3500269A4 (enExample)
JP (2) JP2019524889A (enExample)
KR (1) KR20190065252A (enExample)
CN (1) CN109843292A (enExample)
AU (1) AU2017313842A1 (enExample)
BR (1) BR112019003133A2 (enExample)
CA (1) CA3033971A1 (enExample)
EA (1) EA201990513A1 (enExample)
SG (2) SG10202101500WA (enExample)
WO (1) WO2018035449A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010651A (es) * 2000-04-28 2003-03-10 Sankyo Co Moduladores de receptor activado de proliferador de peroxisoma-gamma.
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
SG11201505944QA (en) * 2013-01-30 2015-08-28 Intekrin Therapeutics Inc PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
TWI699200B (zh) * 2014-10-10 2020-07-21 英商邊緣生物科技有限公司 用於預防及治療骨質疏鬆症之經取代之芳族化合物及醫藥組合物

Also Published As

Publication number Publication date
AU2017313842A1 (en) 2019-03-07
EA201990513A1 (ru) 2019-08-30
SG10202101500WA (en) 2021-03-30
WO2018035449A1 (en) 2018-02-22
US20190167660A1 (en) 2019-06-06
BR112019003133A2 (pt) 2019-05-21
EP3500269A4 (en) 2020-04-15
JP2019524889A (ja) 2019-09-05
KR20190065252A (ko) 2019-06-11
SG11201901328VA (en) 2019-03-28
EP3500269A1 (en) 2019-06-26
CN109843292A (zh) 2019-06-04
JP2022116294A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
US11324735B2 (en) Method of treatment with tradipitant
RU2746000C2 (ru) Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US20160038517A1 (en) Osteoclast Inhibitors Such As Zoledronic Acid For Low Back Pain Treatment
US12201614B2 (en) Methods for treating heterotopic ossification
JP2018162321A (ja) Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
US9867816B2 (en) PPARγ agonists for treatment of multiple sclerosis
JP2022116294A (ja) 骨疾患の治療のためのＰＰＡＲγアゴニスト
JP7546579B2 (ja) 変形性関節症の治療における使用のためのシルデナフィル
JP6011982B2 (ja) 骨形成促進剤及びその用途
Ebeling et al. Teriparatide (rhPTH 1–34) for the treatment of osteoporosis
JP2005526022A5 (ja) 関節リウマチの処置
JP2019524889A5 (enExample)
El Miedany Geroscience and management of osteoporosis in older adults
Winkelmann Evidence for better response to somatostatin analogue treatment in acromegalic patients treated with metformin
CN106794190A (zh) 奈立膦酸或其盐用于治疗骨关节炎的用途
Cusano et al. Newer Adult Bone Drugs
CN101448496A (zh) 治疗遗传性血色病的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220817